ERBB2 and breast cancer: These results support the potential role of the PI3K/AKT/mTOR signaling in controlling de novo lipogenesis in HER2-positive breast cancer cells and show that PI3K inhibitors can decrease MUFAs production by inhibiting SCD-1 expression.